Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AMRX logo

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)AMRX

Upturn stock ratingUpturn stock rating
Amneal Pharmaceuticals, Inc. Class A Common Stock
$8.7
Delayed price
Profit since last BUY3.82%
Consider higher Upturn Star rating
upturn advisory
BUY since 38 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/16/2024: AMRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -38.99%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 25
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/16/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -38.99%
Avg. Invested days: 25
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/16/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.55B USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -0.78
Volume (30-day avg) 1059695
Beta 1.18
52 Weeks Range 3.96 - 8.95
Updated Date 11/5/2024
Company Size Mid-Cap Stock
Market Capitalization 2.55B USD
Price to earnings Ratio -
1Y Target Price 9.5
Dividends yield (FY) -
Basic EPS (TTM) -0.78
Volume (30-day avg) 1059695
Beta 1.18
52 Weeks Range 3.96 - 8.95
Updated Date 11/5/2024

Earnings Date

Report Date 2024-11-08
When BeforeMarket
Estimate 0.13
Actual -
Report Date 2024-11-08
When BeforeMarket
Estimate 0.13
Actual -

Profitability

Profit Margin -6.72%
Operating Margin (TTM) 13.74%

Management Effectiveness

Return on Assets (TTM) 6.09%
Return on Equity (TTM) -148.99%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE 6.3
Enterprise Value 5235096516
Price to Sales(TTM) 0.98
Enterprise Value to Revenue 2.03
Enterprise Value to EBITDA 15.03
Shares Outstanding 309543008
Shares Floating 141383586
Percent Insiders 54.31
Percent Institutions 44.08
Trailing PE -
Forward PE 6.3
Enterprise Value 5235096516
Price to Sales(TTM) 0.98
Enterprise Value to Revenue 2.03
Enterprise Value to EBITDA 15.03
Shares Outstanding 309543008
Shares Floating 141383586
Percent Insiders 54.31
Percent Institutions 44.08

Analyst Ratings

Rating 4
Target Price 5.6
Buy 2
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Rating 4
Target Price 5.6
Buy 2
Strong Buy 1
Hold 1
Sell -
Strong Sell -

AI Summarization

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX): A Comprehensive Overview

Company Profile:

History and Background:

Amneal Pharmaceuticals, Inc. (AMRX) is a New Jersey-based pharmaceutical company founded in 1989. It began as a small generic drug manufacturer and has grown through acquisitions and internal development to become a leading global player in the generic and specialty pharmaceutical market. AMRX currently markets over 175 generic products and several branded offerings across various therapeutic areas.

Core Business Areas:

  • Generics: AMRX's core business revolves around developing, manufacturing, and marketing generic versions of off-patent brand-name drugs. These generics cover a wide range of therapeutic categories, including cardiovascular, central nervous system, anti-infective, and gastrointestinal.
  • Specialty Pharmaceuticals: AMRX also focuses on developing and marketing branded specialty pharmaceuticals. These products address unmet medical needs in niche therapeutic areas, such as dermatology, pain management, and oncology.

Leadership and Corporate Structure:

  • Leadership: Mr. Chintu Patel serves as Chairman and CEO of AMRX. The leadership team comprises experienced professionals with expertise in various aspects of the pharmaceutical industry.
  • Corporate Structure: AMRX operates through a decentralized structure with separate business units dedicated to generics and specialty pharmaceuticals. This allows for focused attention and expertise in each segment.

Top Products and Market Share:

Top Products:

  • Ropinirole ER (Requip XL): A branded dopamine agonist used to treat Parkinson's disease and restless leg syndrome.
  • Gabapentin Capsules: A generic anticonvulsant used to treat epilepsy and nerve pain.
  • Amlodipine Besylate Tablets: A generic calcium channel blocker used to treat hypertension.

Market Share:

  • AMRX holds a significant market share in the generic drug market, particularly for certain high-volume medications.
  • In the US market, AMRX ranks among the top 10 generic drug companies by volume.
  • The company's market share in specialty pharmaceuticals is smaller, but growing steadily.

Product Performance and Market Reception:

  • AMRX's generic products generally receive positive market reception due to their affordability and efficacy.
  • The company's specialty pharmaceuticals have demonstrated strong growth potential, with Ropinirole ER achieving significant market penetration.
  • AMRX faces competition from other generic and branded drug manufacturers, requiring constant innovation and strategic partnerships.

Total Addressable Market:

The global pharmaceutical market is vast, valued at over $1.2 trillion in 2022. The generic drug market represents a significant portion, estimated at over $300 billion. The branded specialty pharmaceutical market is also substantial, with numerous niche therapeutic areas offering growth opportunities.

Financial Performance:

Recent Financial Statements:

  • Revenue: AMRX generated approximately $1.8 billion in revenue for the fiscal year 2022.
  • Net Income: The company reported a net income of around $148 million in 2022.
  • Profit Margin: AMRX's profit margin stands at around 8%, indicating moderate profitability.
  • Earnings per Share (EPS): EPS for 2022 was reported at $0.78.

Financial Performance Comparison:

  • AMRX's revenue and net income have shown moderate year-over-year growth in recent years.
  • Profit margin has remained relatively stable.
  • EPS has fluctuated slightly but maintained a positive trend.

Cash Flow and Balance Sheet Health:

  • AMRX maintains a healthy cash flow position with stable operating cash flow.
  • The company's balance sheet exhibits moderate debt levels and sufficient liquidity.

Dividends and Shareholder Returns:

Dividend History:

  • AMRX has a history of paying dividends, with a recent annual dividend yield of approximately 1.5%.
  • The company's dividend payout ratio is moderate, indicating potential for future dividend increases.

Shareholder Returns:

  • AMRX's stock price has experienced moderate volatility in recent years, with total shareholder returns varying depending on the investment horizon.

Growth Trajectory:

Historical Growth:

  • AMRX has demonstrated consistent revenue and earnings growth over the past five years.
  • This growth is primarily driven by the expansion of the company's generic and specialty pharmaceutical portfolios.

Future Growth Projections:

  • Analysts project moderate future growth for AMRX, fueled by continued generic drug market penetration and the successful launch of new specialty pharmaceuticals.
  • Recent product launches and strategic partnerships indicate the company's commitment to growth initiatives.

Market Dynamics:

Industry Overview:

  • The pharmaceutical industry is characterized by intense competition, technological advancements, and regulatory complexities.
  • The generic drug market is particularly competitive, with numerous players vying for market share.
  • The specialty pharmaceutical market offers higher profit margins but requires significant investment in research and development.

AMRX's Positioning:

  • AMRX is well-positioned within the generic drug market due to its established product portfolio and efficient manufacturing capabilities.
  • The company's focus on niche specialty pharmaceuticals offers diversification and growth potential.
  • AMRX's adaptability to market changes is evident in its strategic partnerships and investments in technology.

Competitors:

Key Competitors:

  • Teva Pharmaceutical Industries Ltd. (TEVA)
  • Mylan N.V. (MYL)
  • Pfizer Inc. (PFE)
  • Allergan, an AbbVie Company (AGN)

Market Share and Comparison:

  • AM

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Amneal Pharmaceuticals, Inc. Class A Common Stock

Exchange NYSE Headquaters Bridgewater, NJ, United States
IPO Launch date 2009-01-15 Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel
Sector Healthcare Website https://amneal.com
Industry Drug Manufacturers - Specialty & Generic Full time employees 7850
Headquaters Bridgewater, NJ, United States
Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel
Website https://amneal.com
Website https://amneal.com
Full time employees 7850

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​